Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.
Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L, Ganly P, Palumbo A, Cavo M, Langer C, Pluta A, Nagler A, Kumar S, Ben-Yehuda D, Rajkumar SV, San-Miguel J, Berg D, Lin J, van de Velde H, Esseltine DL, di Bacco A, Moreau P, Richardson PG.
Avet-Loiseau H, et al. Among authors: viterbo l.
Blood. 2017 Dec 14;130(24):2610-2618. doi: 10.1182/blood-2017-06-791228. Epub 2017 Oct 20.
Blood. 2017.
PMID: 29054911
Free article.
Clinical Trial.